Plasma Amyloid-β 42/40 Assays Compared in Alzheimer Disease
|
By LabMedica International staff writers Posted on 14 Oct 2021 |

Image: Simoa is an ultra-sensitive immunoassay technology that allow detection of proteins and nucleic acids at lowest possible levels (Photo courtesy of Quanterix)
Blood-based tests for brain amyloid-β (Aβ) pathology are needed for widespread implementation of Alzheimer disease (AD) biomarkers in clinical care and to facilitate patient screening and monitoring of treatment responses in clinical trials.
Reliable measurements of Aβ in blood proved challenging until the development of advanced mass spectrometry and immunodetection methods. Recent articles have suggested that Aβ42/40 quantified using ultrasensitive and fully automated immunoassay platforms could predict Aβ-PET status (especially when combined with APOE genotype) with accuracy approaching that of MS-based Aβ42/40 measures.
An international team led by Clinical Neuroscientists at Lund University (Lund, Sweden) compared the performance of plasma Aβ42/40 measured using eight different Aβ assays when detecting abnormal brain Aβ status in patients with early AD. The study included 182 cognitively unimpaired participants and 104 patients with mild cognitive impairment who were enrolled at three different hospitals in Sweden and underwent Aβ positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) and plasma collection from 2010 to 2014.
Plasma Aβ42/40 was measured using an immunoprecipitation-coupled mass spectrometry developed at Washington University School of Medicine (IP-MS-WashU, St Louis, MO, USA), antibody-free liquid chromatography MS developed by Araclon (LC-MS-Arc, Zaragoza, Spain), and diverse immunoassays. Plasma Aβ42/40 was also measured using an IP-MS–based method from Shimadzu (Kyoto, Japan) in 200 participants (IP-MS-Shim) and an IP-MS–based method from the University of Gothenburg (IP-MS-UGOT, Gothenburg, Sweden) and another immunoassay, the N4PE Simoa immunoassay (IA-Quan, Quanterix Billerica, MA, USA) among 227 participants.
When the team identified participants with abnormal CSF Aβ42/40 in the whole cohort, plasma IP-MS-WashU Aβ42/40 showed significantly higher accuracy than LC-MS-Arc Aβ42/40, and some immunoassays. Plasma IP-MS-WashU Aβ42/40 performed significantly better than IP-MS-UGOT Aβ42/40 and IA-Quan Aβ42/40, while there was no difference in the AUCs between IP-MS-WashU Aβ42/40 and IP-MS-Shim Aβ42/40) in the two sub-cohorts where these biomarkers were available. Plasma IPMS-WashU Aβ42/40 and IP-MS-Shim Aβ42/40 showed highest coefficients for correlations with CSF Aβ42/40.
The authors concluded that the results from two independent cohorts indicate that certain MS-based methods performed better than most of the immunoassays for plasma Aβ42/40 when detecting brain Aβ pathology. The study was published on September 20, 2021 in the journal JAMA Neurology.
Related Links:
Lund University
Washington University School of Medicine
Araclon
University of Gothenburg
Quanterix
Reliable measurements of Aβ in blood proved challenging until the development of advanced mass spectrometry and immunodetection methods. Recent articles have suggested that Aβ42/40 quantified using ultrasensitive and fully automated immunoassay platforms could predict Aβ-PET status (especially when combined with APOE genotype) with accuracy approaching that of MS-based Aβ42/40 measures.
An international team led by Clinical Neuroscientists at Lund University (Lund, Sweden) compared the performance of plasma Aβ42/40 measured using eight different Aβ assays when detecting abnormal brain Aβ status in patients with early AD. The study included 182 cognitively unimpaired participants and 104 patients with mild cognitive impairment who were enrolled at three different hospitals in Sweden and underwent Aβ positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) and plasma collection from 2010 to 2014.
Plasma Aβ42/40 was measured using an immunoprecipitation-coupled mass spectrometry developed at Washington University School of Medicine (IP-MS-WashU, St Louis, MO, USA), antibody-free liquid chromatography MS developed by Araclon (LC-MS-Arc, Zaragoza, Spain), and diverse immunoassays. Plasma Aβ42/40 was also measured using an IP-MS–based method from Shimadzu (Kyoto, Japan) in 200 participants (IP-MS-Shim) and an IP-MS–based method from the University of Gothenburg (IP-MS-UGOT, Gothenburg, Sweden) and another immunoassay, the N4PE Simoa immunoassay (IA-Quan, Quanterix Billerica, MA, USA) among 227 participants.
When the team identified participants with abnormal CSF Aβ42/40 in the whole cohort, plasma IP-MS-WashU Aβ42/40 showed significantly higher accuracy than LC-MS-Arc Aβ42/40, and some immunoassays. Plasma IP-MS-WashU Aβ42/40 performed significantly better than IP-MS-UGOT Aβ42/40 and IA-Quan Aβ42/40, while there was no difference in the AUCs between IP-MS-WashU Aβ42/40 and IP-MS-Shim Aβ42/40) in the two sub-cohorts where these biomarkers were available. Plasma IPMS-WashU Aβ42/40 and IP-MS-Shim Aβ42/40 showed highest coefficients for correlations with CSF Aβ42/40.
The authors concluded that the results from two independent cohorts indicate that certain MS-based methods performed better than most of the immunoassays for plasma Aβ42/40 when detecting brain Aβ pathology. The study was published on September 20, 2021 in the journal JAMA Neurology.
Related Links:
Lund University
Washington University School of Medicine
Araclon
University of Gothenburg
Quanterix
Latest Clinical Chem. News
- VOCs Show Promise for Early Multi-Cancer Detection
- Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
- Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis
- Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy
- Simple Non-Invasive Hair-Based Test Could Speed ALS Diagnosis
- Paper Strip Saliva Test Detects Elevated Uric Acid Levels Without Blood Draws
- Prostate Cancer Markers Based on Chemical Make-Up of Calcifications to Speed Up Detection
- Breath Test Could Help Detect Blood Cancers
- ML-Powered Gas Sensors to Detect Pathogens and AMR at POC
- Saliva-Based Cancer Detection Technology Eliminates Need for Complex Sample Preparation
- Skin Swabs Could Detect Parkinson’s Years Before Symptoms Appear
- New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs

- New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
- Pen-Like Tool Quickly and Non-Invasively Detects Opioids from Skin
- Simple Urine Test Could Detect Multiple Cancers at Early Stage
- Earwax Test Accurately Detects Parkinson’s by Identifying Odor Molecules
Channels
Molecular Diagnostics
view channel
New Diagnostic Method Detects Pneumonia at POC in Low-Resource Settings
Pneumonia continues to be one of the leading causes of death in low- and middle-income countries, where limited access to advanced laboratory infrastructure hampers early and accurate diagnosis.... Read more
Blood Immune Cell Analysis Detects Parkinson’s Before Symptoms Appear
Early diagnosis of Parkinson’s disease remains one of the greatest challenges in neurology. The condition, which affects nearly 12 million people globally, is typically identified only after significant... Read moreHematology
view channel
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more
Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more
Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read moreImmunology
view channel
Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
Immunotherapy has revolutionized cancer care by harnessing the immune system to fight tumors, yet predicting who will benefit remains a major challenge. Many patients undergo costly and taxing treatment... Read more
Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
Modern cancer immunotherapies rely on the ability of CD8⁺ T cells to rapidly multiply within tumors, generating the immune force needed to eliminate cancer cells. However, the biological triggers behind... Read moreMicrobiology
view channel
High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample
Gastrointestinal (GI) infections are among the most common causes of illness worldwide, leading to over 1.7 million deaths annually and placing a heavy burden on healthcare systems. Conventional diagnostic... Read more
Fast Noninvasive Bedside Test Uses Sugar Fingerprint to Detect Fungal Infections
Candida bloodstream infections are a growing global health threat, causing an estimated 6 million cases and 3.8 million deaths annually. Hospitals are particularly vulnerable, as weakened patients after... Read morePathology
view channel
New Molecular Analysis Tool to Improve Disease Diagnosis
Accurately distinguishing between similar biomolecules such as proteins is vital for biomedical research and diagnostics, yet existing analytical tools often fail to detect subtle structural or compositional... Read more
Tears Offer Noninvasive Alternative for Diagnosing Neurodegenerative Diseases
Diagnosing and monitoring eye and neurodegenerative diseases often requires invasive procedures to access ocular fluids. Ocular fluids like aqueous humor and vitreous humor contain valuable molecular information... Read moreTechnology
view channel
Cell-Sorting Device Uses Electromagnetic Levitation to Precisely Direct Cell Movement
Sorting different cell types—such as cancerous versus healthy or live versus dead cells—is a critical task in biology and medicine. However, conventional methods often require labeling, chemical exposure,... Read more
Embedded GPU Platform Enables Rapid Blood Profiling for POC Diagnostics
Blood tests remain a cornerstone of medical diagnostics, but traditional imaging and analysis methods can be slow, costly, and reliant on dyes or contrast agents. Now, scientists have developed a real-time,... Read moreIndustry
view channel
Qiagen Acquires Single-Cell Omics Firm Parse Biosciences
QIAGEN (Venlo, Netherlands) has entered into a definitive agreement to fully acquire Parse Biosciences (Seattle, WA, USA), a provider of scalable, instrument-free solutions for single-cell research.... Read more
Puritan Medical Products Showcasing Innovation at AMP2025 in Boston
Puritan Medical Products (Guilford, ME, USA), the world’s most trusted manufacturer of swabs and specimen collection devices, is set to exhibit at AMP2025 in Boston, Massachusetts, from November 11–15.... Read more
Advanced Instruments Merged Under Nova Biomedical Name
Advanced Instruments (Norwood, MA, USA) and Nova Biomedical (Waltham, MA, USA) are now officially doing business under a single, unified brand. This transformation is expected to deliver greater value... Read more








